The CW will broadcast Savannah Bananas baseball madness as network leans into live sports
Baseball isn't boring and the CW isn't stupid, at least when it comes to the Savannah Bananas, the Georgia-based team that has rewritten the rules around the classic American pastime. The network has picked up rights to broadcast the July 27 Bananas game at Citizen's Bank Park in Philadelphia.
"Banana Ball" incorporates humor, gymnastics, lip syncs and snappy dance choreography in a minor league baseball game with rules that definitely don't match those of Major League Baseball — though many of the players once had MLB aspirations. This year the team has sold out 18 major league ballparks, plus three football stadiums with capacities of more than 70,000.
Advertisement
Read more: Going bananas: Why Savannah Bananas tickets cost more than a Dodgers-Yankees rematch
The CW in recent years has been leaning into live sports coverage, which has generally been delivering ratings results in a rapidly changing TV-viewing landscape. The network has the NASCAR Xfinity Series, WWE NXT on Tuesday nights, Grand Slam Track, AVP beach volleyball on summer Saturdays, ACC and Pac-12 football games in the fall and, starting next year, PBA professional bowling.
The Savannah Bananas come with a built-in audience earned via posts on TikTok, Facebook Reels and the like. The team has 10 million followers on TikTok alone.
'We've always been very clear about our goal,' Bananas owner Jesse Cole told The Times in 2022. 'We exist to make baseball fun.'
Advertisement
'It's all about energy. We want to give people energy, delivering it every second, from the moment we open the gates at two o'clock until the last fan leaves at 11," he added over the weekend, when the team played to a sellout crowd at Anaheim Stadium.
Read more: Meet the Savannah Bananas, who've captivated fans and MLB. 'We exist to make baseball fun'
There's definitely an audience appetite for the Savannah team: There are tickets available for games in August and September, but only through a lottery — and the wait list for the lottery is more than 3 million names long. Last season's games drew a million fans total.
On Friday, the only way into the Anaheim game was through the resale market. Hours before the first pitch, the lowest price (fees and taxes included) for a pair of Bananas tickets on StubHub was $209.52, while it took a mere $171.72 to snag a pair of tickets to the Yankees-Dodgers series opener at Dodger Stadium the same night.
Advertisement
Who needs Shohei Ohtani and Aaron Judge anyway: Banana Ball has the Savannah team facing rival outfits the Texas Tailgaters, the Firefighters, the Party Animals and the Visitors.
And while Ohtani and Judge can be counted on for multiple home runs, only the Bananas deliver baby races, a dancing umpire and backflips before balls are caught in the outfield. Plus the games are limited to two hours max, something even the much-loved MLB pitch clock can't deliver.
Read more: Dropped Aaron Judge ball sold by MLB (not Dodgers) gets $43,510 in auction
'The Savannah Bananas have taken the sports world by storm through their high-energy blend of baseball and entertainment that connects with viewers of all ages,' Mike Perman, senior vice president of CW Sports, said in a statement Tuesday.
Advertisement
'We are thrilled to partner with them for their broadcast television debut, and we cannot wait to bring our audience every unpredictable play in front of what promises to be an electric atmosphere in Philadelphia.'
'Banana Ball on The CW is a no-brainer,' Bananas owner Cole added in that news release. "After seeing their recent commitment to sports, we knew this could be a great partnership. With the speed and entertainment of Banana Ball, we look forward to creating new fans together in the years to come.'
Times staff writer David Wharton and Times fellow Anthony De Leon contributed to this report.
Sign up for Screen Gab, a free newsletter about the TV and movies everyone's talking about from the L.A. Times.
This story originally appeared in Los Angeles Times.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
27 minutes ago
- Yahoo
Sydnexis Announces European Commission Approval of SYD-101, the First and Only Pharmaceutical Treatment for Slowing the Progression of Pediatric Myopia
Exclusive-Licensing Partner Santen Will Commercialize SYD-101 Under the Brand Name Ryjunea® in the European Union DEL MAR, Calif., June 05, 2025--(BUSINESS WIRE)--Sydnexis, Inc., ( a pre-commercial stage biopharmaceutical company today announced that the European Commission (EC) has granted marketing authorization for SYD-101, the company's proprietary low-dose atropine formulation, for slowing the progression of pediatric myopia. As the first and only approved pharmaceutical treatment option to treat myopia progression in EU countries, this approval marks a significant advancement in pediatric eye care. The approval is backed by data from the STAR study, Sydnexis' pivotal Phase 3 clinical trial evaluating its proprietary low-dose atropine formulation to slow the progression of pediatric myopia and the risk of associated co-morbidities in children 3 to 14 years old at treatment initiation. "This marks a significant milestone for Sydnexis and, most importantly, for pediatric patients with progressive myopia, their families, and physicians as the first and only approved pharmaceutical treatment option in Europe," said Perry Sternberg, Chief Executive Officer of Sydnexis. "This approval is an endorsement of the potential benefit SYD-101 can provide to millions of patients globally and reinforces the critical importance of early intervention." The marketing approval from the EC follows the recent positive opinion from the Committee for Medicinal Products for Human Use (CHMP). Santen, a Japan-based company specialized in eye health, offering innovative products and services in over 60 countries worldwide, licensed the rights from Sydnexis to commercialize SYD-101 in the regions of Europe, Middle East, and Africa (EMEA) and will launch SYD-101 under the brand name Ryjunea. "The EU approval of SYD-101 is a recognition of the compelling safety and efficacy data generated from our landmark STAR study," said Patrick Johnson, Ph.D., President of Sydnexis. "This validates the potential benefit that SYD-101 can provide to pediatric myopes in Europe and we are excited about our continued interactions with the Food and Drug Administration (FDA) leading up to our October 23 PDUFA date." Myopia is the most common eye disease in children, impacting approximately one-third of children and adolescents worldwide. By 2050, global prevalence is projected to increase and affect more than 740 million children and adolescents and 5 billion people in total. Once considered a benign refractive condition, even at low levels, myopia is now associated with many serious irreversible sight-threatening co-morbidities later in life. "As a Pediatric Ophthalmologist with a rapidly growing number of myopia patients around the world, the EU approval of SYD-101 is truly exciting and it provides an important new tool for physicians to combat this global epidemic," said Dr. Donny Suh, Gavin Herbert Eye Institute, University of California at Irvine. "The benefits of low-dose atropine have long been recognized in the eye care community, but we now finally have an approved and thoroughly vetted treatment option. This marks a new era in our ability to slow the progression of myopia and protect the vision of millions of children worldwide." About Sydnexis, Inc.: Founded in 2014, Sydnexis, Inc. ( is a privately held, pre-commercial stage biopharmaceutical company based in San Diego, California. Sydnexis recently completed its three-year primary endpoint in the pivotal Phase 3 clinical trial evaluating its proprietary low-dose atropine formulation to slow progression of pediatric myopia and the risk of associated co-morbidities. The Phase 3 clinical trial is now completing the fourth-year randomized withdrawal for exploratory endpoints and third year results will be announced upon completion of the fourth year of the study. The company is venture-backed by four major investors: Visionary Ventures, RA Capital, Longitude Capital, and Bluestem Capital. View source version on Contacts For media inquiries, please contact: media@
Business Insider
30 minutes ago
- Business Insider
Billionaire GOP megadonor Ken Griffin is confused: Why is the US trying to bring back 'jobs that'll never pay much'?
Ken Griffin had no good answer. The billionaire founder of the $66 billion hedge fund Citadel and its sister company, market maker Citadel Securities, Griffin is a megadonor to the Republican Party and was excited for the American economy after President Donald Trump's election. Less than half a year since Trump's inauguration, Griffin said he was asked during a recent visit to China, "Why are you trying to be like China?" He said there isn't a logical reason the US would want to bring manufacturing "jobs that'll never pay much" to the country, but that seems to be the goal of the tariff policies pursued by Trump's administration. "It's one thing to make Nikes, it's another thing to make F-35 fighters," he said Thursday morning at the Forbes Iconoclast conference in Manhattan. Griffin has been critical of the administration's tariff policies in recent months, calling them a mistake that will hurt the economy and consumers. He said Thursday that they were an "anti-growth agenda," and the expected growth of the US economy has been cut in half since Trump took office. He continued his criticism of Trump, whom he voted for, focusing on the current tax bill, which was passed by the House of Representatives and is now in the Senate. Griffin said it will add "several trillions" of dollars to the deficit and lacks "tough decisions." "The United States' fiscal house is not in order," Griffin said, questioning the decision to cut taxes on small and medium-sized businesses when the deficit was rising. He said credit markets have noted the uncertainty plaguing the US thanks to the administration's policies, noting that "the risk of a US default is priced the same as Italy or Greece." "There's just no words for it," he said. If there was any optimism in his talk, it was about the resilience of American CEOs. He said hiring and capital expenditures will slow as long as there is uncertainty from Washington. Still, he was impressed with how individuals like Doug McMillon, the CEO of Walmart, explained the impact tariffs would have on the consumer. "We should not criticize CEOs for being honest," he said, adding, "shame on the administration" for scolding McMillon and other CEOs for talking about the tariffs' impact. There's still time for Trump and his team to return to pro-growth economic policies, he said, and there's no time to wait. "The United States desperately needs growth" to pay for entitlements like Social Security, he said.
Yahoo
32 minutes ago
- Yahoo
Electric truck startup Bollinger exits bankruptcy after paying back founder who sued
Electric truck startup Bollinger Motors has exited U.S. bankruptcy court thanks to more financial aid from parent Mullen Automotive Inc., whose chief has ambitious plans for a rebound set in Michigan. California-based Mullen acquired an additional 21 percent of Bollinger, bringing its ownership stake in the suburban Detroit company to 95 percent, Mullen announced June 2 as it executed its second reverse stock split in as many months to stay compliant with Nasdaq rules on share prices. In tandem with Mullen's transaction, Bollinger was discharged from bankruptcy court, its receiver removed and case dismissed with prejudice, according to a filing in U.S. District Court in Detroit. Mullen Automotive CEO David Michery said the company paid $11 million to Robert Bollinger, who in March sued the company he founded, claiming it was broke and seeking to recover his loan. Sign up for the weekly Automotive News Mobility Report newsletter for the latest developments at the intersection of transportation and technology. Mullen, which has faced a host of financial issues beyond Bollinger, is all-in on the EV startup, Michery said June 4 during an interview with Automotive News and affiliate Crain's Detroit Business. Bollinger Motors — despite the spat with its namesake — will persevere as a brand that 'will outlast everyone,' Michery vowed at the startup's Oak Park, Mich., headquarters. 'You can't blame Bollinger for the current market, you can't blame Bollinger for tariffs, you can't blame Bollinger for the disruption that occurred with Robert filing this frivolous lawsuit,' Michery said. 'That hurt the company.' Now, Mullen is putting its chips on Bollinger Motors to weather the storm. Michery said production of Class 4 trucks would resume in 8 to10 weeks and that its staff of about 85 in metro Detroit would soon swell in line with a predicted increase in demand — though that remains in question with a stagnant market. Mullen will close its engineering base in Irvine, Calif., and consolidate it to the company's tech center near Detroit in Troy, Mich., where 40-50 employees will be added, Michery said. 'I want all engineering, all manufacturing, everything in the state of Michigan,' he said. While Michery serves as CEO of Bollinger Motors, the company's daily operations will be overseen by James Taylor, who will return to the company as a consultant after departing in March. Another priority is cleaning up the company's supply chain. Bollinger Motors has been sued by several suppliers claiming they were being stiffed by the startup. Michery said he is in the process of paying debts, including to contract manufacturer Roush, which makes the class 4 trucks for Bollinger. Mullen's earnings reports to the SEC seem to indicate big financial trouble. It lost $162 million on revenue of $7.9 million in the first quarter; it posted a $115 million loss on revenue of $2.9 million in the prior quarter. The company lost its 675,000-square-foot former AM General factory in Mishawaka, Ind., last month to settle a financial dispute with creditor GEM Yield Bahamas Ltd. However, Michery said the company has ample liquidity, including a $150 million equity line allowing the company to use its stock as currency — an instrument approved by the SEC and shareholders. 'Picture a credit card,' he said. 'Mullen has a $150 million credit card that it can use at will.' Mullen's 1-for-100 reverse stock split executed Monday was designed to bring its stock price above $1 per share to meet Nasdaq requirements. Financial adviser Alex Calderone said the move is window dressing and does not solve underlying business performance issues. 'I would not surmise that would impact company valuation at all or shareholder rights at all,' Calderone said. 'It just appears to be a cosmetic change to be able to adjust the share price. … It's like if I traded you a hundred dollar bill for a hundred singles.' On Wednesday, Mullen's stock shot up to above $16 per share, tripling its value over the course of a day, as Michery pointed out after pulling up the market summary on his phone. He said: 'They knew we were coming out here to put Bollinger back in business.' Have an opinion about this story? Tell us about it and we may publish it in print. Click here to submit a letter to the editor. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
